Drug Firm That Sells $1,000 Brain Cancer Pill Drops Medicare Program

DISCOUNT DENIED

It dropped out after hiking the price from $50 over the course of a decade.

Published Jun. 17 2021 12:46PM EDT

2017-07-20T214838Z_488846854_RC11176340C0_RTRMADP_3_USA-JOHNMCCAIN-GLIOBLASTOMA_qcfhh9 — Reuters

Over the last eight years, the pharmaceutical company NextSource has hiked the price of a drug for brain cancer patients from $50 to $1,000 a pill, even though the patent for it is expired.

Tracy Connor

Got a tip? Send it to The Daily Beast here.

Drug Firm That Sells $1,000 Brain Cancer Pill Drops Medicare Program

It dropped out after hiking the price from $50 over the course of a decade.

We think “subscriber” would look good on you. Join now to unlock access.

Don't miss this subscriber exclusive article.

Monthly Plan

$1 Trial

Yearly Plan

$35 Year One

Ad Free Plan

$100 per year

Tracy Connor